CredoScientia - Bibliothèque

Multimodal Conversion Therapy Enabling Curative Resection in Giant Hepatocellular Carcinoma with Arteriovenous Fistula: A Case Report.

BACKGROUND: Giant hepatocellular carcinoma (GHCC) with arteriovenous fistula (AVF) is often considered a surgical no-go zone, lacking a standardized conversion therapy. This paper reports a case in wh…

Thérapies de Conversion

Zhong, H., Tan, L., Le, W., Luo, N., Shen, Y., Long, G., Xiong, C., & Tao, H. (2026). Multimodal Conversion Therapy Enabling Curative Resection in Giant Hepatocellular Carcinoma with Arteriovenous Fistula: A Case Report.. J Hepatocell Carcinoma, 13, 599120. https://doi.org/10.2147/JHC.S599120

01/01/2026 Lire →

TACE Combined with Targeted Immunotherapy: A Strategy for Liver Transplantation Conversion and Survival Benefits in Patients with BCLC Stage B/C HCC.

BACKGROUND: Patients with BCLC stage B or C hepatocellular carcinoma (HCC) often face long waiting times. The effectiveness of different tumor control strategies remains unclear. This study evaluates …

Thérapies de Conversion

Zhang, H., Zhang, X., Zhang, L., Wang, S., & Ma, Y. (2026). TACE Combined with Targeted Immunotherapy: A Strategy for Liver Transplantation Conversion and Survival Benefits in Patients with BCLC Stage B/C HCC.. J Hepatocell Carcinoma, 13, 588533. https://doi.org/10.2147/JHC.S588533

01/01/2026 Lire →

The survival impact of upfront or sequential chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.

BACKGROUND: The treatment of locally advanced unresectable esophageal squamous cell carcinoma (ESCC) is a clinical challenge with limited therapeutic consensus. The immune checkpoint inhibitor (ICI)-b…

Thérapies de Conversion

Luo, X., Peng, F., Lin, X., Li, Y., & Ding, Z. (2026). The survival impact of upfront or sequential chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.. Front Oncol, 16, 1785745. https://doi.org/10.3389/fonc.2026.1785745

01/01/2026 Lire →

Gastric cancer, what's new from International Gastric Cancer Congress (IGCC) in Amsterdam: a scientific report from Salerno 2025 conference.

This paper presents a critical synthesis of the national conference "Gastric Cancer at Ruggi d'Aragona", held in Salerno, Italy, in June 2025. The event gathered over 200 specialists to discuss recent…

Thérapies de Conversion

Cattel, D., Albano, P. V., Feo, R., Pepe, S., & Puzziello, A. (2026). Gastric cancer, what's new from International Gastric Cancer Congress (IGCC) in Amsterdam: a scientific report from Salerno 2025 conference.. Ecancermedicalscience, 20, 2083. https://doi.org/10.3332/ecancer.2026.2083

01/01/2026 Lire →

Hepatitis B virus infection and outcomes of TACE plus lenvatinib and PD-1 inhibitor therapy in unresectable hepatocellular carcinoma: a real-world propensity score-matched study.

BACKGROUND: The combination of transarterial chemoembolization (TACE), lenvatinib, and PD-1 inhibitors has shown promising efficacy in treating advanced hepatocellular carcinoma (HCC). However, the im…

Thérapies de Conversion

Su, Y., Liang, Y., Zhong, D., Chen, Y., Ma, S., Wang, M., Yang, Q., Yan, H., & Huang, X. (2026). Hepatitis B virus infection and outcomes of TACE plus lenvatinib and PD-1 inhibitor therapy in unresectable hepatocellular carcinoma: a real-world propensity score-matched study.. Front Immunol, 17, 1808956. https://doi.org/10.3389/fimmu.2026.1808956

01/01/2026 Lire →

The Impact of Spatiotemporal Patterns of Tumor Recurrence on Prognosis in Hepatocellular Carcinoma Patients Undergoing Surgery After Conversion Therapy.

PURPOSE: To characterize the spatiotemporal patterns of recurrence and assess their impact on survival in hepatocellular carcinoma (HCC) patients undergoing curative resection after conversion therapy…

Thérapies de Conversion

Chen, Z., Zheng, H., Piao, M., Zhang, L., Sun, Y., Zhang, K., Zhang, J., Liu, Y., Xu, Y., & Lu, X. (2026). The Impact of Spatiotemporal Patterns of Tumor Recurrence on Prognosis in Hepatocellular Carcinoma Patients Undergoing Surgery After Conversion Therapy.. J Hepatocell Carcinoma, 13, 599046. https://doi.org/10.2147/JHC.S599046

01/01/2026 Lire →

Stereotactic body radiation therapy for hepatocellular carcinoma: a comprehensive review.

Hepatocellular carcinoma (HCC) presents significant challenges in modern surgical and radiation oncology, primarily due to biological heterogeneity and the complexities of underlying liver cirrhosis. …

Thérapies de Conversion

Di, Y., Ren, G., Wang, Y., Meng, L., & Li, J. (2026). Stereotactic body radiation therapy for hepatocellular carcinoma: a comprehensive review.. Front Oncol, 16, 1747449. https://doi.org/10.3389/fonc.2026.1747449

01/01/2026 Lire →

Clinical Efficacy Exploration of Temperature-Sensitive Embolic Agent TACE Combined with HAIC and Targeted/Immunotherapy for Unresectable Primary Liver Cancer.

OBJECTIVE: To evaluate the efficacy and safety of TEM-TACE combined with HAIC and targeted/immunotherapy for the treatment of unresectable primary liver cancer, and to clarify the clinical application…

Thérapies de Conversion

Chen, X., Xiao, H., Lan, X., & Du, C. (2026). Clinical Efficacy Exploration of Temperature-Sensitive Embolic Agent TACE Combined with HAIC and Targeted/Immunotherapy for Unresectable Primary Liver Cancer.. J Hepatocell Carcinoma, 13, 572484. https://doi.org/10.2147/JHC.S572484

01/01/2026 Lire →

Pathologic response and safety of preoperative treatment regimens in gastric cancer undergoing D2 gastrectomy: a real-world cohort study.

OBJECTIVE: To compare pathological response and safety among three preoperative treatment regimens-chemotherapy alone, chemotherapy plus immunotherapy, and chemotherapy plus immunotherapy and targeted…

Thérapies de Conversion

Liu, P., Li, N., Guo, J., Wang, J., Wang, Z., Zhao, G., Mou, Z., & Mao, J. (2026). Pathologic response and safety of preoperative treatment regimens in gastric cancer undergoing D2 gastrectomy: a real-world cohort study.. Front Immunol, 17, 1766793. https://doi.org/10.3389/fimmu.2026.1766793

01/01/2026 Lire →

Surgery vs. non-surgery for advanced cholangiocarcinoma post-conversion therapy with PD-1/PD-L1 inhibitors plus TKIs.

OBJECTIVE: To compare overall survival (OS) and progression-free survival (PFS) between surgical resection and non-surgical therapy in initially unresectable Cholangiocarcinoma (CCA) patients who achi…

Thérapies de Conversion

Sun, Z., Wang, Y., Chen, X., Yang, L., Li, O., Zhou, J., Tan, Z., & Peng, C. (2026). Surgery vs. non-surgery for advanced cholangiocarcinoma post-conversion therapy with PD-1/PD-L1 inhibitors plus TKIs.. Front Immunol, 17, 1753437. https://doi.org/10.3389/fimmu.2026.1753437

01/01/2026 Lire →

Clinical outcomes with first-line tislelizumab plus lenvatinib in unresectable hepatocellular carcinoma: a retrospective analysis.

PURPOSE: This retrospective analysis aimed to assess the therapeutic efficacy and adverse event profile of tislelizumab combined with lenvatinib in patients with unresectable hepatocellular carcinoma …

Thérapies de Conversion

Lin, J., Zhou, Q., Yao, Z., Wang, Q., Xu, S., Xiong, Z., Dang, X., Liang, H., & Liu, B. (2026). Clinical outcomes with first-line tislelizumab plus lenvatinib in unresectable hepatocellular carcinoma: a retrospective analysis.. PeerJ, 14, e20591. https://doi.org/10.7717/peerj.20591

01/01/2026 Lire →

Impact of HER2 and microsatellite instability status on response to neoadjuvant/conversion therapy and survival in patients with gastric cancer.

OBJECTIVES: The prognostic significance of microsatellite instability (MSI) and HER2 status in advanced gastric cancer (AGC) treated with neoadjuvant or conversion chemotherapy (NAC) remains unclear. …

Thérapies de Conversion

Piccioni, S. A., Costantini, M., Petrioli, R., Bagnacci, G., Ferrara, D., Andreucci, E., Carbone, L., Ongaro, A., Calomino, N., Sandini, M., Mazzei, M. A., Roviello, F., & Marrelli, D. (2026). Impact of HER2 and microsatellite instability status on response to neoadjuvant/conversion therapy and survival in patients with gastric cancer.. Eur J Cancer Prev, 35(1), 66-77. https://doi.org/10.1097/CEJ.0000000000000982

01/01/2026 Lire →